Literature DB >> 23987661

Commentary on: Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement.

Carole Spencer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23987661      PMCID： PMC3783929          DOI： 10.1089/thy.2013.0496

Source DB:  PubMed          Journal:  Thyroid        ISSN： 1050-7256            Impact factor:   6.568


× No keyword cloud information.
  7 in total

1.  Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease.

Authors:  Zubair Baloch; Pierre Carayon; Bernard Conte-Devolx; Laurence M Demers; Ulla Feldt-Rasmussen; Jean-François Henry; Virginia A LiVosli; Patricia Niccoli-Sire; Rhys John; Jean Ruf; Peter P A Smyth; Carole A Spencer; Jan R Stockigt
Journal:  Thyroid       Date:  2003-01       Impact factor: 6.568

Review 2.  Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement.

Authors:  Frederik A Verburg; Markus Luster; Cristina Cupini; Luca Chiovato; Leonidas Duntas; Rossella Elisei; Ulla Feldt-Rasmussen; Harald Rimmele; Ettore Seregni; Johannes W A Smit; Christian Theimer; Luca Giovanella
Journal:  Thyroid       Date:  2013-08-03       Impact factor: 6.568

3.  Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer.

Authors:  C Spencer; I Petrovic; S Fatemi
Journal:  J Clin Endocrinol Metab       Date:  2011-02-16       Impact factor: 5.958

Review 4.  Clinical review: Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC).

Authors:  Carole A Spencer
Journal:  J Clin Endocrinol Metab       Date:  2011-09-14       Impact factor: 5.958

Review 5.  Thyroglobulin antibody (TgAb) methods - Strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer.

Authors:  Carole Spencer; Shireen Fatemi
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2013-08-12       Impact factor: 4.690

Review 6.  Clinical review: improving the measurement of serum thyroglobulin with mass spectrometry.

Authors:  Andrew N Hoofnagle; Mara Y Roth
Journal:  J Clin Endocrinol Metab       Date:  2013-02-28       Impact factor: 5.958

7.  Thyroglobulin autoantibodies in patients with papillary thyroid carcinoma: comparison of different assays and evaluation of causes of discrepancies.

Authors:  Francesco Latrofa; Debora Ricci; Lucia Montanelli; Roberto Rocchi; Paolo Piaggi; Eleonora Sisti; Lucia Grasso; Fulvio Basolo; Clara Ugolini; Aldo Pinchera; Paolo Vitti
Journal:  J Clin Endocrinol Metab       Date:  2012-09-04       Impact factor: 5.958
  7 in total
  8 in total

Review 1.  Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita
Journal:  Thyroid       Date:  2015-07       Impact factor: 6.568

2.  Clinical Usefulness of F-18 FDG PET/CT in Papillary Thyroid Cancer with Negative Radioiodine Scan and Elevated Thyroglobulin Level or Positive Anti-thyroglobulin Antibody.

Authors:  Su Jung Choi; Kyung Pyo Jung; Sun Seong Lee; Yun Soo Park; Seok Mo Lee; Sang Kyun Bae
Journal:  Nucl Med Mol Imaging       Date:  2015-10-22

3.  Difficulties in deciding whether to ablate patients with putatively "low-intermediate-risk" differentiated thyroid carcinoma: do guidelines mainly apply in the centres that produce them? Results of a retrospective, two-centre quality assurance study.

Authors:  Savvas Frangos; Ioannis P Iakovou; Robert J Marlowe; Nicolaos Eftychiou; Loukia Patsali; Anna Vanezi; Androulla Savva; Vassilis Mpalaris; Evanthia I Giannoula
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-01       Impact factor: 9.236

4.  Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications.

Authors:  Carole Spencer; Ivana Petrovic; Shireen Fatemi; Jonathan LoPresti
Journal:  J Clin Endocrinol Metab       Date:  2014-12       Impact factor: 5.958

Review 5.  How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies.

Authors:  Carole Spencer; Jonathan LoPresti; Shireen Fatemi
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-10       Impact factor: 3.243

6.  Antithyroglobulin Antibody as a Marker of Successful Ablation Therapy in Differentiated Thyroid Cancer.

Authors:  Ayu Rosemeilia Dewi; Budi Darmawan; Achmad Hussein Sundawa Kartamihadja; Basuki Hidayat; Johan S Masjhur
Journal:  World J Nucl Med       Date:  2017 Jan-Mar

7.  A Multiplex Thyroid-Specific Assay for Quantification of Circulating Thyroid Cell-Free RNA in Plasma of Thyroid Cancer Patients.

Authors:  Samantha Peiling Yang; Lian Chye Winston Koh; Kiat Whye Kong; Rajeev Parameswaran; Kelvin Siu Hoong Loke; Kee Yuan Ngiam; Wee Boon Tan; Thomas Loh; David Chee Eng Ng; Boon Cher Goh; Joanne Ngeow; E Shyong Tai
Journal:  Front Genet       Date:  2021-08-25       Impact factor: 4.599

8.  Change in Antithyroglobulin Antibody Levels is a Good Predictor of Responses to Therapy in Antithyroglobulin Antibody-Positive Pediatric Papillary Thyroid Carcinoma Patients.

Authors:  Chuang Xi; Guo-Qiang Zhang; Hong-Jun Song; Chen-Tian Shen; Li-Ying Hou; Zhong-Ling Qiu; Quan-Yong Luo
Journal:  Int J Endocrinol       Date:  2022-03-10       Impact factor: 3.257
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.